AI Drug Discovery Reaches 173 Active Clinical Programs With New FDA Framework
A comprehensive analysis counts 173 active AI-discovered drug programs in clinical development, supported by an evolving FDA framework for credibility assessment of AI models used in drug discovery.
A comprehensive industry analysis has identified 173 active clinical programs involving AI-discovered or AI-designed drug candidates — a number that has grown rapidly from fewer than 50 just two years ago. The analysis spans programs from early Phase I through late-stage pivotal trials across oncology, neuroscience, immunology, and infectious disease.
The growth reflects both the maturation of AI drug discovery platforms and increasing pharmaceutical industry adoption. Major pharma companies have moved beyond pilot partnerships to embedding AI deeply in their discovery pipelines, while AI-native biotechs continue to advance their own clinical programs.
A critical enabling factor has been the FDA's evolving regulatory stance. The agency published draft guidance in January 2025 outlining a risk-based credibility assessment framework for AI models used in drug discovery and development. This framework provides manufacturers with clearer expectations for how to validate and document AI tools used in the discovery process.
The next 12-18 months will be decisive. With 15-20 AI-discovered drugs expected to enter pivotal Phase III trials in 2026, the field will finally have large-scale clinical data to answer the fundamental question: does AI actually improve the probability of clinical success, or does it primarily compress timelines and reduce costs in early discovery?